you Music Music Music so so you you Bye. Dear investors, good afternoon. Welcome to the 3-Quarter Results Summary Session of Sunwu Shares 2024. The co-leaders of this performance statement will be Mr. Zhang Chongyu, the chairman, Ms. Zhang Jing, the vice-chairman and president, Mr. Li, the financial director and secretary-general, Ms. Geng Ming, the independent director. This statement will be divided into two parts. The first part is the interpretation of the report on the third quarter of the 2024 biotech ...

证券代码：600201 证券简称：生物股份 公告编号：临 2024-049 金宇生物技术股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 （一） 会议召开时间：2024 年 11 月 28 日 下午 15:00-16:30 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2024 年 11 月 28 日(星期四) 下午 15:00-16:30 会 议 召 开 地 点 ： 上海证券 交易所上证路演中心（ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2024 年 11 月 21 日(星期四) 至 11 月 27 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stock@jinyu.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 金宇生物技术股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日 披露公司《2024 年第三季 ...

金宇生物技术股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日召开 第十一届董事会第十七次会议，会议审议通过《关于以集中竞价交易方式回购公 司股份的议案》，具体内容详见公司于 2024 年 10 月 31 日在上海证券交易所网站 （www.sse.com.cn）披露的《金宇生物技术股份有限公司关于以集中竞价交易方 式回购公司股份的回购报告书》（公告编号：临 2024-045）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，现将公司董事会公告回购股份决议的前一个交易 日（即 2024 年 10 月 30 日）登记在册的前十大股东和前十大无限售条件股东的名 称、持股数量及持股比例情况公告如下： | 序号 | 股东名称 | 持股数量(股) | 占公司股份总 数的比例(%) | | --- | --- | --- | --- | | 1 | 内蒙古金宇生物控股有限公司 | 122,304,000 | 10.92 | | 2 | 伟星资产管理（上海）有限公司－宁波 梅山保税港区星棋道和股权投资合伙企 业（有限合伙） | 42,347,655 | ...

证券代码：600201 证券简称：生物股份 公告编号：临2024-047 金宇生物技术股份有限公司关于 以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/10/31 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | 预计回购金额 | 8,000 万元~16,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 0 万股 | | 累计已回购股数占总股本比例 | 0% | | 累计已回购金额 | 0 元 | | 实际回购价格区间 | 无 | 金宇生物技术股份有限公司（以下简称"公司"）于 2024 年 10 月 30 日召开第 十一届董事会第十七次会议，会议审议并通过《关于以集中竞价交易方式回购公司 股份的议案》，同意公司使用自有资金以集中竞价交易方式回购公司股份用于实施 员工持股 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company's performance is under short-term pressure, with a significant decline in revenue and net profit for the first three quarters of 2024. However, the company has a strong innovation capability and a sufficient reserve of new products for continuous growth, leading to the maintained "Buy" rating [2][3]. Financial Performance Summary - For Q1-Q3 2024, the company reported revenue of 971 million yuan, a year-on-year decrease of 20.36%, and a net profit attributable to shareholders of 170 million yuan, down 41.19%. In Q3 alone, revenue was 359 million yuan, down 32.79%, with a net profit of 47 million yuan, down 69.70% [2]. - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 277 million yuan, 380 million yuan, and 455 million yuan respectively, with corresponding EPS of 0.25 yuan, 0.34 yuan, and 0.41 yuan. The current stock price corresponds to P/E ratios of 26.9, 19.6, and 16.4 times for the respective years [2][5]. Product and Market Analysis - The company's revenue from foot-and-mouth disease vaccines accounted for over 40% of total revenue in Q1-Q3 2024. The competitive landscape has intensified, impacting overall operations. However, revenue from pseudorabies and blue ear vaccines continues to grow [3]. - The company has seen a significant increase in market share for non-foot-and-mouth products. Revenue from sheep vaccines grew by 30% year-on-year, reaching over 20 million yuan, despite some decline in revenue and gross margin for brucellosis vaccines due to delayed government procurement [3]. - The poultry vaccine segment has shown improvement, with revenue from avian influenza vaccines increasing, although conventional poultry vaccine prices remain under pressure [3]. Research and Development - The company emphasizes R&D investment, with R&D expenses of 88 million yuan in Q1-Q3 2024. The company is actively involved in the emergency evaluation of non-epidemic vaccines and is progressing well with mRNA vaccine registrations [4]. - The company has a robust pipeline of new products, with a completed offline distributor system and ongoing online channel development, ensuring a strong growth trajectory [4].

证券代码：600201 证券简称：生物股份 公告编号：临 2024-046 金宇生物技术股份有限公司 关于子公司取得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据国家《兽药管理条例》和《兽药注册办法》规定，经国家农业农村部审 查，批准金宇生物技术股份有限公司（以下简称"公司"）全资子公司金宇保灵 生物药品有限公司（以下简称"金宇保灵"）参与研制开发的布鲁氏菌病活疫苗 （S19 株）为新兽药，并核发了《新兽药注册证书》。详情如下： 一、新兽药产品基本情况 新兽药名称：布鲁氏菌病活疫苗（S19 株） 注册分类：三类 新兽药注册证书号：(2024)新兽药证字63号 研制单位：金宇保灵生物药品有限公司、山东信得科技股份有限公司 主要成分与含量：本品含牛种布鲁氏菌 S19 株。每头份疫苗含活菌数应为 6.0×1010CFU～1.2×1011CFU。 作用与用途：用于预防牛布鲁氏菌病。免疫期为 48 个月。 用法与用量： （1）皮下注射。一般仅对 3～8 月龄牛接种，每头接种 1 头份，必要时，可 在第一 ...

证券代码：600201 证券简称：生物股份 公告编号：临 2024-043 金宇生物技术股份有限公司 第十一届董事会第十七次会议决议公告 表决结果：8 票同意、0 票反对、0 票弃权。 具体内容详见公司披露在上海证券交易所网站（www.sse.com.cn）上的《金 宇生物技术股份有限公司 2024 年第三季度报告》。 二、审议并通过《关于以集中竞价交易方式回购公司股份的议案》 为了维护公司及全体股东的利益，增强投资者信心，进一步建立、健全公司 长效激励机制，公司拟通过集中竞价交易方式，以自有资金回购部分公司社会公 众股，用于员工持股计划或股权激励。本次回购股份资金总额不低于人民币 8,000 万元，不超过人民币 16,000 万元。具体内容详见公司披露在上海证券交易所网站 （www.sse.com.cn）上的《金宇生物技术股份有限公司关于以集中竞价交易方式 回购公司股份的回购报告书》（公告编号：临 2024-045）。 特此公告。 金宇生物技术股份有限公司 董 事 会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物 ...

证券代码：600201 证券简称：生物股份 编号：临2024-045 金宇生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 相关股东是否存在减持计划：公司董事、监事、高级管理人员、持股 5%以 上股东内蒙古金宇生物控股有限公司(以下简称"生物控股")及其一致行动人未 来 3 个月、未来 6 个月不存在减持计划。如上述主体未来拟实施股份减持计划，公 司将遵守中国证监会和上海证券交易所关于股份减持的相关规定，及时履行信息披 露义务。 相关风险提示 1、本次回购股份期限内，若公司股票价格持续超出回购方案披露的回购价格 上限，存在回购方案无法顺利实施的风险； 2、若发生对公司股票交易价格产生重大影响的重大事项, 或公司生产经营、 财务状况、外部客观情况发生重大变化，可能存在公司董事会根据相关规则决定终 止本次回购方案的风险； 3、本次回购的股份将用于员工持股计划或股权激励, 可能存在因相关方案未 能经公司董事会和股东大会审议通过、激励对象放弃认购等原因 ...

Revenue and Profit - Revenue for Q3 2024 was CNY 359,073,392.22, a decrease of 32.79% year-over-year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 46,622,327.14, down 69.70% compared to the same period last year[2] - Basic earnings per share for Q3 2024 was CNY 0.04, a decline of 71.43% year-over-year[3] - The company reported a decrease in net profit attributable to shareholders for the year-to-date period of 41.19%[7] - Total operating revenue for the first three quarters of 2024 was CNY 970,804,600.73, a decrease of 20.3% compared to CNY 1,218,989,228.41 in the same period of 2023[16] - Net profit for the third quarter of 2024 was CNY 170,256,021.00, down 40.4% from CNY 285,758,448.43 in the same quarter of 2023[18] - The net profit attributable to the parent company shareholders for the third quarter was approximately ¥169.54 million, a decrease from ¥288.31 million in the same period last year, representing a decline of about 41.2%[19] - The total comprehensive income attributable to the parent company owners was approximately ¥161.84 million, down from ¥288.47 million year-over-year, indicating a decrease of around 43.8%[19] - The basic and diluted earnings per share for the third quarter were both ¥0.15, compared to ¥0.26 in the previous year, reflecting a decline of approximately 42.3%[19] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 211,278,277.27, down 28.49% year-over-year[2] - Cash inflows from operating activities totaled approximately ¥1.01 billion, down from ¥1.26 billion in the same period last year, representing a decrease of about 19.6%[21] - The net cash flow from operating activities was approximately ¥211.28 million, compared to ¥295.45 million in the same period last year, a decrease of around 28.5%[21] - The net cash flow from investing activities was negative at approximately -¥297.66 million, compared to -¥237.24 million in the previous year, indicating a worsening of about 25.5%[22] - The net cash flow from financing activities was negative at approximately -¥96.82 million, contrasting with a positive cash flow of ¥111.84 million in the same period last year[22] - The total cash and cash equivalents at the end of the period were approximately ¥869.58 million, down from ¥1.44 billion at the end of the previous year, reflecting a decrease of about 39.6%[22] Assets and Liabilities - Total assets as of the end of Q3 2024 were CNY 6,903,124,320.81, representing a slight increase of 0.44% from the end of the previous year[3] - As of September 30, 2024, the company's total current assets amounted to approximately CNY 2.45 billion, a decrease of 18.8% from CNY 3.02 billion on December 31, 2023[13] - The company's cash and cash equivalents decreased from CNY 1.71 billion at the end of 2023 to CNY 1.28 billion, reflecting a decline of 25.3%[13] - Accounts receivable decreased from CNY 857.49 million to CNY 745.12 million, a reduction of 13.1%[13] - Inventory decreased from CNY 322.25 million to CNY 283.08 million, a decline of 12.2%[13] - The company's long-term equity investments slightly decreased from CNY 266.28 million to CNY 263.27 million, a decrease of 1.1%[13] - The total non-current assets increased from CNY 2.56 billion to CNY 2.58 billion, reflecting a growth of 0.8%[13] - The company's fixed assets increased from CNY 1.52 billion to CNY 1.63 billion, an increase of 5.4%[13] - Total liabilities increased to CNY 1,353,964,961.43 from CNY 1,217,642,217.42, representing a rise of 11.2%[15] Expenses - Total operating costs decreased to CNY 775,774,038.75 from CNY 896,303,403.85, reflecting a reduction of 13.5%[16] - Research and development expenses for the third quarter of 2024 were CNY 88,026,265.74, compared to CNY 109,253,292.83 in the same quarter of 2023, indicating a decrease of 19.4%[18] - The company reported a decrease in sales expenses to CNY 194,238,768.85 from CNY 226,879,602.40, a reduction of 14.4%[18] Shareholder Information - The largest shareholder, Inner Mongolia Jinyu Biological Holdings Co., Ltd., holds 10.92% of the shares, with 23,780,000 shares pledged[8] - The company has not reported any significant changes in shareholder participation in margin trading and securities lending activities[11] Other Information - The company experienced a significant decline in revenue due to intensified industry competition and changes in product sales structure[6] - Non-recurring gains for Q3 2024 amounted to CNY 7,922,872.21, with a year-to-date total of CNY 22,977,722.67[5] - The company's weighted average return on equity decreased by 2.08 percentage points to 0.86% for Q3 2024[3] - There are no other important reminders regarding the company's operational situation during the reporting period[13] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[23]

金宇生物技术股份有限公司(以下简称"公司")第十一届监事会第十五次会 议通知于 2024 年 10 月 15 日以电子邮件、书面形式发出，会议于 2024 年 10 月 30 日下午 15:00 在公司会议室以现场和通讯表决相结合的方式召开，应出席监事 3 人，实际出席监事 3 人。会议的召集、召开程序符合《公司法》及《公司章程》 的规定。会议由监事会主席董人美女士主持，审议并通过了如下议案： 审议并通过《公司 2024 年第三季度报告》 证券代码：600201 证券简称：生物股份 公告编号：临 2024-044 金宇生物技术股份有限公司 第十一届监事会第十五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决结果：3 票同意、0 票反对、0 票弃权。 公司监事会对董事会编制的 2024 年第三季度报告进行了审核，并发表意见如 下： 1、公司 2024 年第三季度报告编制和审议程序符合法律、法规、《公司章程》 和公司内部管理制度的各项规定； 2、公司 2024 年第三季度报告的内容和格式符合中国证监会和上海证券 ...